FLT3 and glycogen storage disease VI: Taken together, our analyses suggest HMA pretreatment, extramedullary disease and the mutation status of NF1, PTPN11, FLT3, TP53 and SF3B1 as clinically relevant predictors of survival in patients treated with HMA/VEN for R/R AML.